PA8747601A1 - Marcaciòn con fluor radioactivo - Google Patents

Marcaciòn con fluor radioactivo

Info

Publication number
PA8747601A1
PA8747601A1 PA20078747601A PA8747601A PA8747601A1 PA 8747601 A1 PA8747601 A1 PA 8747601A1 PA 20078747601 A PA20078747601 A PA 20078747601A PA 8747601 A PA8747601 A PA 8747601A PA 8747601 A1 PA8747601 A1 PA 8747601A1
Authority
PA
Panama
Prior art keywords
radioactive
fluor
marking
compounds
marked
Prior art date
Application number
PA20078747601A
Other languages
English (en)
Inventor
Klar Ulrich
Srinivasan Ananth
Lehmann Lutz
Stellfeld Timo
Ametamey Simon
Voigtmann Ulrike
Hoehne Aileen
Mu Linjing
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06076823A external-priority patent/EP1908472A1/en
Priority claimed from EP06076869A external-priority patent/EP1911452A1/en
Priority claimed from EP07090043A external-priority patent/EP1970064A1/en
Priority claimed from EP07090079A external-priority patent/EP1985624A3/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PA8747601A1 publication Critical patent/PA8747601A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0896—Compounds with a Si-H linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/12—Organo silicon halides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Nuclear Medicine (AREA)

Abstract

NUEVOS COMPUESTOS ADECUADOS PARA SER MARCADOS O YA MARCADOS RADIOACTIVAMENTE CON 18F, MÉTODOS PARA PREPARAR DICHOS COMPUESTOS Y USO DE LOS MISMOS PARA DIAGNÓSTICO POR IMÁGENES. LOS COMPUESTOS RADIOACTIVOS SE CARACTERIZAN POR LA FÓRMULA II, EN LA CUAL F, R¹, R², B1,2, Y1,2, Z1,2 Y E TIENEN LOS VALORES QUE SE DEFINEN EN LA MEMORIA DESCRIPTIVA Y LAS REIVINDICACIONES.
PA20078747601A 2006-10-02 2007-09-14 Marcaciòn con fluor radioactivo PA8747601A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06076823A EP1908472A1 (en) 2006-10-02 2006-10-02 Silicon derivatives for PET imaging
EP06076869A EP1911452A1 (en) 2006-10-11 2006-10-11 Silicon-derivates for PET-Imaging
EP07090043A EP1970064A1 (en) 2007-03-12 2007-03-12 Silicon-derivatives for pet-imaging
EP07090079A EP1985624A3 (en) 2007-04-23 2007-04-23 Single step method of radiofluorination of biologically active compounds or biomolecules

Publications (1)

Publication Number Publication Date
PA8747601A1 true PA8747601A1 (es) 2009-08-26

Family

ID=39030886

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20078747601A PA8747601A1 (es) 2006-10-02 2007-09-14 Marcaciòn con fluor radioactivo

Country Status (21)

Country Link
US (1) US20090035215A1 (es)
EP (1) EP2074135A2 (es)
JP (1) JP2010505776A (es)
KR (1) KR20090085599A (es)
AR (1) AR062795A1 (es)
AU (1) AU2007304508A1 (es)
BR (1) BRPI0719956A2 (es)
CA (1) CA2664700A1 (es)
CO (1) CO6180444A2 (es)
CR (1) CR10703A (es)
IL (1) IL197817A0 (es)
MA (1) MA30824B1 (es)
MX (1) MX2009003617A (es)
NO (1) NO20091735L (es)
PA (1) PA8747601A1 (es)
PE (1) PE20081173A1 (es)
SV (1) SV2009003205A (es)
TN (1) TN2009000100A1 (es)
TW (1) TW200820988A (es)
UY (1) UY30596A1 (es)
WO (1) WO2008040441A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627486T3 (es) 2010-01-25 2017-07-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Biomoléculas sililadas
JP5717138B2 (ja) * 2011-05-23 2015-05-13 独立行政法人産業技術総合研究所 タンパク質固定化表面修飾材料
WO2014196540A1 (ja) * 2013-06-06 2014-12-11 日産化学工業株式会社 アルコキシシラン化合物、液晶配向剤、液晶配向膜及び液晶表示素子
US10800797B2 (en) 2015-05-26 2020-10-13 California Institute Of Technology Heteroaromatic silicon-fluoride-acceptors useful for 18F labeling of molecules and biomolecules, and methods of preparing same
WO2019055825A1 (en) 2017-09-15 2019-03-21 The Regents Of The University Of California INHIBITION OF AMINOACYLASE 3 (AA3) IN THE TREATMENT OF CANCER
WO2021226076A1 (en) * 2020-05-04 2021-11-11 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for detection of bacterial infection
EP4218831A4 (en) * 2020-09-28 2024-03-06 National Institutes for Quantum Science and Technology METHOD FOR PRODUCING A RADIOACTIVELY LABELED SUBSTANCE, DEVICE FOR PRODUCING A RADIOACTIVELY LABELED SUBSTANCE AND METHOD FOR THE VAPORIZATION AND CONCENTRATION OF RADIOACTIVE METAL NUCLIDE

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084555A (en) * 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
US5732578A (en) * 1995-02-24 1998-03-31 Hyundai Metal Co., Ltd. Device for maintaining the horizontality of a door lock lever
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6639076B1 (en) * 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
JP2003502314A (ja) * 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物
AU2002228725A1 (en) * 2000-11-30 2002-06-11 Advanced Research And Technology Institute, Inc. Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds
GB0206750D0 (en) * 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
US7342095B2 (en) * 2003-02-20 2008-03-11 University Of South Florida Peptidomimetic inhibitors of STAT activity and uses thereof
GB0305704D0 (en) * 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
EP1723161A4 (en) * 2004-02-13 2010-04-28 Univ British Columbia RADIOACTIVELY MARKED COMPOUNDS AND COMPOSITIONS, PRECURSORS AND METHOD FOR THE PRODUCTION THEREOF
US20080029548A1 (en) * 2006-05-05 2008-02-07 Ann De Wree Fabric treatment dispensing package

Also Published As

Publication number Publication date
EP2074135A2 (en) 2009-07-01
CR10703A (es) 2009-06-25
PE20081173A1 (es) 2008-11-06
KR20090085599A (ko) 2009-08-07
TW200820988A (en) 2008-05-16
IL197817A0 (en) 2009-12-24
JP2010505776A (ja) 2010-02-25
TN2009000100A1 (en) 2010-08-19
UY30596A1 (es) 2008-05-02
CA2664700A1 (en) 2008-04-10
SV2009003205A (es) 2009-10-19
MA30824B1 (fr) 2009-10-01
CO6180444A2 (es) 2010-07-19
WO2008040441A2 (en) 2008-04-10
AR062795A1 (es) 2008-12-03
NO20091735L (no) 2009-06-30
WO2008040441A3 (en) 2009-01-08
US20090035215A1 (en) 2009-02-05
AU2007304508A1 (en) 2008-04-10
MX2009003617A (es) 2009-04-22
BRPI0719956A2 (pt) 2014-04-29
AU2007304508A8 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
PA8747601A1 (es) Marcaciòn con fluor radioactivo
DOP2015000264A (es) Derivados de azaadamantano y métodos de uso de los mismos
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
CR10654A (es) Agentes que comprenden compuestos marcados con 18f y metodos relacionados
NO20071880L (no) Diagnostic Compounds
ECSP10010344A (es) Azolilmetiloxiranos, su uso y agentes que los contienen
AR057237A1 (es) Metodos y composiciones para actuar sobre la poliubiquitina
CL2007002094A1 (es) Combinaciones que contienen cetoenoles ciclicos y al menos uno de los compuestos cienopirafeno, ciflumetofeno, e ika2002; agentes que las comprenden y procedimiento de preparacion; procedimiento para combatir plagas animales; y uso de las mismas.
BRPI0809346A2 (pt) Compostos derivados substituídos de imidazopiridina e composição farmacêutica contendo os mesmos
BRPI0606112A2 (pt) 3 - heteroaril - 3 - hidróxi - 2 - amino - propil aminas e compostos relacionados, bem como uso dos mesmos e composição farmacêutica
BRPI0813341A2 (pt) " uso de compostos, composições curáveis, e, uso de composições curáveis ".
BRPI0617479A2 (pt) método e composição útil para manter ou melhorar a saúde gastrintestiinal de um animal, kit, meio para comunicação de informações ou instruções, e, uso de uma composição
CR20140135A (es) Nuevos derivados de aril-quinolina
CR9786A (es) Compuestos de bencimidazol-tiofeno
CL2009000404A1 (es) Compuestos derivados de piperidin-indol-sustituidos, moduladores de receptores nociceptina/orl1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades del snc, cardiovasculares, metabolicas, entre otras.
PA8747701A1 (es) Métodos de marcación con flúor radioactivo
GT201000047A (es) Mejoras en compuestos organicos o relacionadas con los mismos
UY30087A1 (es) Piperazinas y piperidinas como potenciadoras de mglur5
BRPI0810399A2 (pt) Composto, composição farmacêutica que o contém e uso do mesmo
EA201301334A1 (ru) Меченные радиоактивными изотопами ингибиторы глутаминилциклазы
DE602006008639D1 (de) Automatisches radioaktives markierungsverafhren
AR063027A1 (es) Derivados de sulfonamida
ECSP10010179A (es) Compuestos fungicidas, procedimientos para su obtención y su uso para combatir hongos nocivos así como agentes que los contienen
BRPI0922908A2 (pt) "composição compreendendo pelo menos dois cicloalquilmeticonas diferentes e uso deste".
CL2009000599A1 (es) Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras.